These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23077486)

  • 1. No association of a set of candidate genes on haloperidol side effects.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    PLoS One; 2012; 7(10):e44853. PubMed ID: 23077486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Friedl M; Konte B; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):887-94. PubMed ID: 22980146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.
    Giegling I; Drago A; Schäfer M; Hartmann AM; Sander T; Toliat MR; Möller HJ; De Ronchi D; Stassen HH; Rujescu D; Serretti A
    Psychopharmacology (Berl); 2011 Apr; 214(3):719-28. PubMed ID: 21079921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of
    Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2023 Dec; 53(4):8-14. PubMed ID: 38076668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
    Heck AH; Haffmans PM; de Groot IW; Hoencamp E
    Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Konte B; Friedl M; Serretti A; Rujescu D
    Pharmacogenet Genomics; 2014 Jun; 24(6):314-9. PubMed ID: 24751813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
    Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
    J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
    Odou P; Vaiva G; Luyckx M; Brunet C; Dine T; Gressier B; Cazin M; Cazin JC
    Eur J Clin Pharmacol; 1996; 50(5):357-63. PubMed ID: 8839656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
    Shim JC; Choe BM; Kim JG; Jae YM; Kim HC; Kim SG; Oh MK; Kelly DL; Conley RR
    J Clin Psychopharmacol; 2007 Aug; 27(4):400-1. PubMed ID: 17632229
    [No Abstract]   [Full Text] [Related]  

  • 15. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
    Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
    Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
    Oosthuizen P; Emsley R; Jadri Turner H; Keyter N
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):125-31. PubMed ID: 15003147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine and haloperidol in first episode psychosis: two-year data.
    Green AI; Lieberman JA; Hamer RM; Glick ID; Gur RE; Kahn RS; McEvoy JP; Perkins DO; Rothschild AJ; Sharma T; Tohen MF; Woolson S; Zipursky RB;
    Schizophr Res; 2006 Sep; 86(1-3):234-43. PubMed ID: 16887334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
    Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
    Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.